Efficacy and safety of sulbactum/cefoperazone for hepato-biliary infections

Nagao Shinagawa; Shozo Takeda; Sei Ichi Oohira; Yoshikazu Yasuda; Masato Fujisaki; Hidetsugu Saito; Masakazu Ueda; Keiji Mitamura; Takeki Nishio; Masaru Itakura; Masaru Koyama; Masanori Hirano; Rempei Ohyama; Makoto Kako; Yoshihisa Amako; Koichi Okuda; Takehiko Iwasa; Atsushi Sugiyama; Makoto Hirano; Shigeki Takashima; Nakaaki Ohsawa; Seishi Nakaya; Minoru Yamada; Fujio Zeze; Shinnosuke Tanaka; Kohta Yatsuka; Jun Ishii

Efficacy and safety of sulbactum/cefoperazone for hepato-biliary infections

Nagao Shinagawa, Shozo Takeda, Sei Ichi Oohira, Yoshikazu Yasuda, Masato Fujisaki, Hidetsugu Saito, Masakazu Ueda, Keiji Mitamura, Takeki Nishio, Masaru Itakura, Masaru Koyama, Masanori Hirano, Rempei Ohyama, Makoto Kako, Yoshihisa Amako, Koichi Okuda, Takehiko Iwasa, Atsushi Sugiyama, Makoto Hirano, Shigeki TakashimaNakaaki Ohsawa, Seishi Nakaya, Minoru Yamada, Fujio Zeze, Shinnosuke Tanaka, Kohta Yatsuka, Jun Ishii

School of Pharmacy

Research output: Contribution to journal › Article › peer-review

Abstract

We studied efficacy and safety of sulbactam/cefoperazone (SBT/CPT) in the treatment of biliary tract infections in hospitalized patients at 26 hospitals from February 1993 to March 1995. Secondary to dropout, 273 out of 338 patients entered in the study were evaluated, 127 patients with cholecystitis, 132 patients with cholangitis, and 14 patients with liver abscesses. Of these, 93 patients (34.1%) had malignancy as an underlying disease. SDT/CPZ had an efficacy of 79.9% (218 patients; excellent: 52, good: 166), with the efficacy in patients with cholecystitis, cholangitis and liver abscess at 89.0% (113 patients), 77.3% (102 patients) and 21.4% (3 patients), respectively. A significant difference (p<0.05) was observed in the efficacy rates of patients with (59 patients [63.4%]) and without malignancy (159 patients [88.3%]). A total of 84 strains were isolated from bile specimens of 53 patients, and the major isolates were Escherichia coli, Pseudomonas aeruginosa and Enterococcus spp. Two or more bacterial strains were isolated simulateously in 20 patients. Mild or moderate side effects (allergic reaction including rash etc.) were noted in 4 patients (1.18%), and laboratory abnormalities (increased GOT, etc.) were in 16 patients (4.71%) out of the total 338 patients. This study clearly demonstrated that SBT/CPZ retains its excellent clinical efficacy and safety profile, throughout its use over the past decade.

Original language	English
Pages (from-to)	13-16
Number of pages	4
Journal	Japanese Journal of Antibiotics
Volume	50
Issue number	11
Publication status	Published - 1997

ASJC Scopus subject areas

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

Fingerprint Dive into the research topics of 'Efficacy and safety of sulbactum/cefoperazone for hepato-biliary infections'. Together they form a unique fingerprint.

Cite this

Shinagawa, N., Takeda, S., Oohira, S. I., Yasuda, Y., Fujisaki, M., Saito, H., Ueda, M., Mitamura, K., Nishio, T., Itakura, M., Koyama, M., Hirano, M., Ohyama, R., Kako, M., Amako, Y., Okuda, K., Iwasa, T., Sugiyama, A., Hirano, M., ... Ishii, J. (1997). Efficacy and safety of sulbactum/cefoperazone for hepato-biliary infections. Japanese Journal of Antibiotics, 50(11), 13-16.

Efficacy and safety of sulbactum/cefoperazone for hepato-biliary infections. / Shinagawa, Nagao; Takeda, Shozo; Oohira, Sei Ichi; Yasuda, Yoshikazu; Fujisaki, Masato; Saito, Hidetsugu; Ueda, Masakazu; Mitamura, Keiji; Nishio, Takeki; Itakura, Masaru; Koyama, Masaru; Hirano, Masanori; Ohyama, Rempei; Kako, Makoto; Amako, Yoshihisa; Okuda, Koichi; Iwasa, Takehiko; Sugiyama, Atsushi; Hirano, Makoto; Takashima, Shigeki; Ohsawa, Nakaaki; Nakaya, Seishi; Yamada, Minoru; Zeze, Fujio; Tanaka, Shinnosuke; Yatsuka, Kohta; Ishii, Jun.

In: Japanese Journal of Antibiotics, Vol. 50, No. 11, 1997, p. 13-16.

Research output: Contribution to journal › Article › peer-review

Shinagawa, N, Takeda, S, Oohira, SI, Yasuda, Y, Fujisaki, M, Saito, H, Ueda, M, Mitamura, K, Nishio, T, Itakura, M, Koyama, M, Hirano, M, Ohyama, R, Kako, M, Amako, Y, Okuda, K, Iwasa, T, Sugiyama, A, Hirano, M, Takashima, S, Ohsawa, N, Nakaya, S, Yamada, M, Zeze, F, Tanaka, S, Yatsuka, K & Ishii, J 1997, 'Efficacy and safety of sulbactum/cefoperazone for hepato-biliary infections', Japanese Journal of Antibiotics, vol. 50, no. 11, pp. 13-16.

Shinagawa, Nagao ; Takeda, Shozo ; Oohira, Sei Ichi ; Yasuda, Yoshikazu ; Fujisaki, Masato ; Saito, Hidetsugu ; Ueda, Masakazu ; Mitamura, Keiji ; Nishio, Takeki ; Itakura, Masaru ; Koyama, Masaru ; Hirano, Masanori ; Ohyama, Rempei ; Kako, Makoto ; Amako, Yoshihisa ; Okuda, Koichi ; Iwasa, Takehiko ; Sugiyama, Atsushi ; Hirano, Makoto ; Takashima, Shigeki ; Ohsawa, Nakaaki ; Nakaya, Seishi ; Yamada, Minoru ; Zeze, Fujio ; Tanaka, Shinnosuke ; Yatsuka, Kohta ; Ishii, Jun. / Efficacy and safety of sulbactum/cefoperazone for hepato-biliary infections. In: Japanese Journal of Antibiotics. 1997 ; Vol. 50, No. 11. pp. 13-16.

@article{8a2951c8880046618d1527aeee3a4b1e,

title = "Efficacy and safety of sulbactum/cefoperazone for hepato-biliary infections",

abstract = "We studied efficacy and safety of sulbactam/cefoperazone (SBT/CPT) in the treatment of biliary tract infections in hospitalized patients at 26 hospitals from February 1993 to March 1995. Secondary to dropout, 273 out of 338 patients entered in the study were evaluated, 127 patients with cholecystitis, 132 patients with cholangitis, and 14 patients with liver abscesses. Of these, 93 patients (34.1%) had malignancy as an underlying disease. SDT/CPZ had an efficacy of 79.9% (218 patients; excellent: 52, good: 166), with the efficacy in patients with cholecystitis, cholangitis and liver abscess at 89.0% (113 patients), 77.3% (102 patients) and 21.4% (3 patients), respectively. A significant difference (p<0.05) was observed in the efficacy rates of patients with (59 patients [63.4%]) and without malignancy (159 patients [88.3%]). A total of 84 strains were isolated from bile specimens of 53 patients, and the major isolates were Escherichia coli, Pseudomonas aeruginosa and Enterococcus spp. Two or more bacterial strains were isolated simulateously in 20 patients. Mild or moderate side effects (allergic reaction including rash etc.) were noted in 4 patients (1.18%), and laboratory abnormalities (increased GOT, etc.) were in 16 patients (4.71%) out of the total 338 patients. This study clearly demonstrated that SBT/CPZ retains its excellent clinical efficacy and safety profile, throughout its use over the past decade.",

author = "Nagao Shinagawa and Shozo Takeda and Oohira, {Sei Ichi} and Yoshikazu Yasuda and Masato Fujisaki and Hidetsugu Saito and Masakazu Ueda and Keiji Mitamura and Takeki Nishio and Masaru Itakura and Masaru Koyama and Masanori Hirano and Rempei Ohyama and Makoto Kako and Yoshihisa Amako and Koichi Okuda and Takehiko Iwasa and Atsushi Sugiyama and Makoto Hirano and Shigeki Takashima and Nakaaki Ohsawa and Seishi Nakaya and Minoru Yamada and Fujio Zeze and Shinnosuke Tanaka and Kohta Yatsuka and Jun Ishii",

year = "1997",

language = "English",

volume = "50",

pages = "13--16",

journal = "The Journal of antibiotics. Ser. B",

issn = "0368-2781",

publisher = "Japan Antibiotics Research Association",

number = "11",

}

TY - JOUR

T1 - Efficacy and safety of sulbactum/cefoperazone for hepato-biliary infections

AU - Shinagawa, Nagao

AU - Takeda, Shozo

AU - Oohira, Sei Ichi

AU - Yasuda, Yoshikazu

AU - Fujisaki, Masato

AU - Saito, Hidetsugu

AU - Ueda, Masakazu

AU - Mitamura, Keiji

AU - Nishio, Takeki

AU - Itakura, Masaru

AU - Koyama, Masaru

AU - Hirano, Masanori

AU - Ohyama, Rempei

AU - Kako, Makoto

AU - Amako, Yoshihisa

AU - Okuda, Koichi

AU - Iwasa, Takehiko

AU - Sugiyama, Atsushi

AU - Hirano, Makoto

AU - Takashima, Shigeki

AU - Ohsawa, Nakaaki

AU - Nakaya, Seishi

AU - Yamada, Minoru

AU - Zeze, Fujio

AU - Tanaka, Shinnosuke

AU - Yatsuka, Kohta

AU - Ishii, Jun

PY - 1997

Y1 - 1997

N2 - We studied efficacy and safety of sulbactam/cefoperazone (SBT/CPT) in the treatment of biliary tract infections in hospitalized patients at 26 hospitals from February 1993 to March 1995. Secondary to dropout, 273 out of 338 patients entered in the study were evaluated, 127 patients with cholecystitis, 132 patients with cholangitis, and 14 patients with liver abscesses. Of these, 93 patients (34.1%) had malignancy as an underlying disease. SDT/CPZ had an efficacy of 79.9% (218 patients; excellent: 52, good: 166), with the efficacy in patients with cholecystitis, cholangitis and liver abscess at 89.0% (113 patients), 77.3% (102 patients) and 21.4% (3 patients), respectively. A significant difference (p<0.05) was observed in the efficacy rates of patients with (59 patients [63.4%]) and without malignancy (159 patients [88.3%]). A total of 84 strains were isolated from bile specimens of 53 patients, and the major isolates were Escherichia coli, Pseudomonas aeruginosa and Enterococcus spp. Two or more bacterial strains were isolated simulateously in 20 patients. Mild or moderate side effects (allergic reaction including rash etc.) were noted in 4 patients (1.18%), and laboratory abnormalities (increased GOT, etc.) were in 16 patients (4.71%) out of the total 338 patients. This study clearly demonstrated that SBT/CPZ retains its excellent clinical efficacy and safety profile, throughout its use over the past decade.

AB - We studied efficacy and safety of sulbactam/cefoperazone (SBT/CPT) in the treatment of biliary tract infections in hospitalized patients at 26 hospitals from February 1993 to March 1995. Secondary to dropout, 273 out of 338 patients entered in the study were evaluated, 127 patients with cholecystitis, 132 patients with cholangitis, and 14 patients with liver abscesses. Of these, 93 patients (34.1%) had malignancy as an underlying disease. SDT/CPZ had an efficacy of 79.9% (218 patients; excellent: 52, good: 166), with the efficacy in patients with cholecystitis, cholangitis and liver abscess at 89.0% (113 patients), 77.3% (102 patients) and 21.4% (3 patients), respectively. A significant difference (p<0.05) was observed in the efficacy rates of patients with (59 patients [63.4%]) and without malignancy (159 patients [88.3%]). A total of 84 strains were isolated from bile specimens of 53 patients, and the major isolates were Escherichia coli, Pseudomonas aeruginosa and Enterococcus spp. Two or more bacterial strains were isolated simulateously in 20 patients. Mild or moderate side effects (allergic reaction including rash etc.) were noted in 4 patients (1.18%), and laboratory abnormalities (increased GOT, etc.) were in 16 patients (4.71%) out of the total 338 patients. This study clearly demonstrated that SBT/CPZ retains its excellent clinical efficacy and safety profile, throughout its use over the past decade.

UR - http://www.scopus.com/inward/record.url?scp=33749302858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749302858&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749302858

VL - 50

SP - 13

EP - 16

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 11

ER -